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Received November 26, 2010; accepted February 25, 2011AbstractBackground: Brain magnetic resonance spectroscopy (MRS) has been reported to be a valuable noninvasive tool in the diagnosis of some rare
diseases. In this study, our aim was to assess lactate peak on single-voxel proton MRS in children with syndromic mitochondrial diseases (MDs).
Methods: From March 2004 to November 2010, 14 patients who were diagnosed with syndromic MDs underwent single-voxel proton MRS
examination. The volume of interest was positioned on axial magnetic resonance imaging (MRI), and voxels were sampled using short (35
milliseconds), intermediate (144 milliseconds), or long (288 milliseconds) echo times for determination of lactate at 1.33 parts/million.
Results: Twelve of fourteen patients (85.7%) exhibited lactate peaks on the initial single-voxel proton MRS, and all of them showed abnormal
MRI findings. The correlations of lactate level in blood and lactate peak on single-voxel proton MRS were inconsistent. Among the 12 patients,
eight (66.7%) had corresponding elevated levels of blood lactate, and four (33.3%) had normal levels of blood lactate. Compared with a positive
rate of 85.7% for patients with lactate peaks on the single-voxel proton MRS, the positive rates for diagnosing syndromic MDs by using electron
microscopic examination of muscle biopsy, oral glucose lactate stimulation test, and blood lactate level were 100%, 91.7%, and 71.4%,
respectively.
Conclusion: Lactate acquisition on single-voxel proton MRS provides a noninvasive and complementary tool for the diagnosis of syndromic
MDs, especially in children with abnormal signal changes on the brain MRI or a normal blood lactate level.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Mitochondrial diseases (MDs) are a group of complex and
heterogeneous disorders characterized by impaired energy
production, which is caused by mutations in mitochondrial
and nuclear genes that lead to oxidative phosphorylation* Corresponding author. Dr. Hsiu-Fen Lee, Department of Pediatrics,
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doi:10.1016/j.jcma.2011.05.006dysfunction. Clinical manifestations of MDs in childhood are
often nonspecific because symptoms may arise from any organ
or system. Although recent advances in genetics have led to the
development of diagnostic tools for many MDs, most of the
patients present with rather challenging diagnostic dilemmas.
Therefore, diagnostic confirmation of a MD is based on
a combination of modalities including clinical features, meta-
bolic survey, histopathologic analysis of muscle specimens,
neuroradiologic findings, and molecular genetic studies.1
In the last decade, the diagnosis of MDs has been greatly
enhanced by advances in neuroimaging. Proton (hydrogen-1hinese Medical Association. All rights reserved.
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in vivo investigation of brain metabolism, has proven to be
useful in the study of certain rare hereditary brain metabolic
disorders such as childhood white matter diseases,2e5 and
brain creatine deficiency syndromes,6 as well as in the clinical
evaluation of phenotypic MDs. The latter includes specific
mitochondrial syndromes, i.e. Leigh syndrome,7 mitochon-
drial encephalopathy, lactic acidosis, and strokelike episodes
(MELAS),8 chronic progressive external ophthalmoplegia
(CPEO),9 nonsyndromic MDs,10,11 and the clinical suspicion
of MDs.12 Furthermore, because of the safety and noninvasive
nature of MRS, it can be repeatedly applied to monitor the
progression and fluctuating course of MDs.13
The aim of this study was to assess lactate peak on brain
MRS in children with syndromic MDs. This finding was
compared with the results of other diagnostic methods relevant
to syndromic MDs including blood lactate level, oral glucose
challenge test, and histopathologic results.
2. Methods
From March 2004 to November 2010, 14 patients, 7 males
and 7 females who were diagnosed with syndromic MDs,
underwent MRS examination. The median age at clinical
presentation was 12months, with a range of 1month to 13 years.
Detailed neurological examination and basic laboratory tests
were performed on all patients. The laboratory tests consisted
of analysis of arterial blood gas, blood lactate level (normal
3e12 mg/dL), and metabolic surveys including assays of blood
amino acids and urinary organic acids. An oral glucose lactate
stimulation test (OGLST)14 and a spinal tap were administrated
to patients after obtaining their parents’ consent, and the lactate
value of cerebrospinal fluid (CSF) (normal 10e25 mg/dL) and
assay of CSF amino acids were determined.
Mitochondrial DNA (mt DNA) common point mutations
(mt 3243, 8344, 8993, and 9176) and mt DNA deletions were
screened. Total DNAwas extracted from peripheral blood using
the Purgene blood DNA isolation kit (Qiagen, Valencia, CA,
USA). The mt DNA point mutation was screened by polymeri-
zation chain reaction-restriction fragment length polymorphism
method, and mt DNA common deletion was screened by duplex
polymerization chain reaction. In cases with the suspicion of
Leigh syndrome, mt genes including mt ND2 through mt ND6,
NDUFS1, NDUFS3, NDUFS4, NDUFS7, NDUFS8, and the
nuclear gene SURF1 were analyzed by direct sequencing.
Written informed consentswere obtained frompatients’ parents.
A skeletal muscle biopsy for light microscopic and electron
microscopic (EM) examinations was performed. Morphological
examination of the skeletal muscle tissue included histochem-
ical stains such as modified Gomori trichrome staining for
ragged-red fibers, adenosine triphosphatase staining for assess-
ment of myofibrillar integrity, muscle-type fiber predominance
and distribution, and cytochrome c oxidase and succinate
dehydrogenase staining for oxidative enzymes.
Definite diagnosis of syndromic MDs was made based on
the modified MDs criteria by Bernier et al.15 The major
criteria included (1) clinically complete respiratory chain(RC) encephalomyopathy including Leigh syndrome, Alpers
disease, lethal infantile MD, Pearson’s syndrome, Kearns-
Sayre syndrome (KSS), mitochondrial encephalomyopathy,
lactic acidosis, and strokelike episodes (MELAS), myoclonic
epilepsy with ragged-red fibers (MERRF), neuropathy, ataxia,
and retinitis pigmentosa (NARP), mitochondrial neuro-gastro-
intestinal encephalomyopathy (MNGIE), Leber hereditary
optic neuropathy (LHON), and deafness dystonia syndrome
(DDs), or a mitochondrial cytopathy including unexplained
combination of multisystemic symptoms, a progressive clinical
course with episodes of exacerbation, and other possible
metabolic or nonmetabolic disorders excluded by appropriate
testing, and (2) molecular identification of a mt DNA mutation
of undisputed pathogenicity. The minor criteria included (1)
histologically abnormal mitochondrial configurations and/or
abnormal subsarcolemmal mitochondrial accumulation of
muscle cells, and (2) an abnormal metabolic indicator of
OGLST. All patients who fulfilled a definitive diagnosis, i.e.
two major criteria or one major criterion plus two minor
criteria, were included in this study.
Brain magnetic resonance imaging (MRI) examinations
were performed on a 1.5-T (Siemens, Sonata, Germany) or
3.0-T (Philips, Achieva X-series, Nederland). Standard 1.5-T
MRI with T1-weighted images [echo time (TE)/repetition
time (TR) 11 ms/550 ms], T2-weighted images (TE/TR 93 ms/
4000 ms), and fluid-attenuated inversion recovery (FLAIR)
(TE/TR/inversion time 110 ms/10000 ms/2250 ms), as well as
3.0-T MRI with T1-weighted images (TE/TR 5 ms/338 ms),
T2-weighted images (TE/TR 80 ms/3000 ms), and FLAIR
[TE/TR/inversion time (TI) 125 ms/11000 ms/2800 ms] were
performed. A volume of interest for MRS was positioned on
the axial MRI with one or multiple regions within the basal
ganglia or lesion sites. Voxels were sampled using one or
multiple echo times, including 35 milliseconds (short), 144
milliseconds (intermediate) or 288 milliseconds (long), with
repetition times of 2000 milliseconds and volumes ranging
from 1.5 mL to 8 mL. Choice of echo time and region was
dependent on the imaging features at the time of the exami-
nation. All spectra were reviewed with a special interest in
lactate level elevation. Spectra were evaluated by comparing
amplitudes of the resonance signals. Peak amplitude was
determined by assuming a Lorentzian line shape and evaluating
the baseline noise standard deviation. Amplitudes of myo-
inositol at 3.56 parts/million (ppm), choline at 3.25 ppm, N-
acetylaspartate at 2.01 ppm, and lactate at 1.33 ppm were
expressed. A peak at a TE of 35 milliseconds, an inverted
doublet at a TE of 144 milliseconds, or a peak at a TE of 288
milliseconds was used to diagnose the acquisition of lactate.
We analyzed the MRS findings in children with syndromic
MDs, which were then compared with the results of other
diagnostic methods including blood lactate level, OGLST, and
histopathologic results.
3. Results
Among 14 patients with syndromic MDs, seven manifested
Leigh syndrome, four exhibited MELAS, one presented with
Fig. 1. Lactate peak on brain MRS in mitochondrial encephalopathy lactic
acidosis and stroke-like episodes (mt A3243G), Case 10. This 9-year-old boy
presents with severe headache, vomiting, right-hand clonic seizures, and short
stature. Axial 1.5 T fluid-attenuated inversion recovery imaging (TE/TR/
inversion time 120 ms/9002 ms/2250 ms) reveals hyperintensity over the left
temporal and occipital areas. A volume of interest is located at the left
occipital area. Magnetic resonance spectroscopy using intermediate echo time
(144 milliseconds) reveals reduced signals of NAA and presence of an obvious
inverted doublet of lactate at 1.33 ppm. Cho ¼ choline, Cr ¼ creatine, NAA ¼
N-acetylaspartate.
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DDs.
As shown in Table 1, 1.5-T and 3.0-T brain MRIs were
performed on 7 patients and 7 patients, respectively. Lactate
peaks on the initial MRS were detected in 12 patients (12 of
14; 85.7%), of which nine (9 of 12; 75.0%) were in acute
deterioration phase of the disease course (Figs. 1 and 2), and
three (3 of 12; 25.0%) were in a stationary period of the
disease process. All 12 patients had abnormal MRI findings.
Two patients without lactate peaks on the initial MRS had
variable MRI features, in which there were signal changes
over the bilateral lentiform nucleus in one case with DDs and
normal MRI feature in one case with CPEO.
Follow-up brain MRS was performed on 4 patients with
either disease progression or stationary clinical course. The
median duration of follow-up was 4 months, with a range of 3
months to 1 year and 11 months. The lactate peaks in 3 cases
became negative: Case 2 with Leigh syndrome was followed
up during the course of disease deterioration, Case 4 with
Leigh syndrome and Case 13 with Pearson syndrome were
examined during the stationary phase of disease course. Case 8
with MELAS had positive lactate peaks on both initial and
follow-up MRS.
Comparisons of lactate peaks on MRS and other diagnostic
methods for syndromic MDs, including measurement of levelsTable 1
Summary of clinical diagnosis, brain MRI and brain MRS findings




MRI findings MRS (single voxel)
Signal changes on T2WI Lactate peak Site interrogated
1st FU
1 6 mo F LS Basal ganglia, dorsal aspects of pons and
medulla, and cerebellar atrophy
þ* (1.5 T) (I) NA Right putamen
2 3 mo M LS Bilateral putamen and thalamus þ (1.5 T) (I) * (1.5 T) (I) Right putamen
3 3 mo M LS Bilateral putamen , dorsal aspects of pons
and medulla, and diffuse cerebral and
cerebellar atrophy
þ* (1.5 T) (I) NA Dorsal aspect of pons
4 6 mo M LS Bilateral putamen þ* (3.0 T) (S, I, L)  (3.0 T) (L) Left putamen
5 14 mo M LS Bilateral putamen and right globus pallidus þ* (3.0 T) (S, L) NA Right putamen
6 4 mo F LS Bilateral putamen, thalamus and brainstem þ* (1.5 T) (I) NA Bilateral putamen
7 1 yr 6 mo F LS Bilateral putamen, and caudate nucleus þ* (3.0 T) (S, I, L) NA Left putamen
8 7 yr F MELAS Cortex and subcortical white matters of
right temporal and parietal areas
þ (3.0 T) (S, I, L) þ* (3.0 T)
(S, I, L)
Right parietal lobe
9 9 yr M MELAS Cortex of bilateral temporal and occipital
lobes, bilateral subcortical white matter of
occipital lobe, and generalized brain
atrophy
þ (3.0 T) (S, L) NA Right temporal lobe
10 9 yr M MELAS Cortex and subcortical white matter of left
parieto-occipital lobe and left thalamus
þ* (1.5 T) (I) NA Left occipital area
11 5 yr 11 mo F MELAS Cortex and subcortical white matter of
bilateral occipital lobes and cortex of
bilateral central and parietal areas
þ* (3.0 T) (S, I, L) NA Left occipital area
12 13 yr F CPEO Normal  (3.0 T) (S, I, L) NA Right putamen
13 1 mo F PS Dorsal aspect of medulla, frontal and
parietal gray matter, and cerebellum
þ* (1.5 T) (S)  (1.5 T) (I) Right frontal gray matter
14 4 mo M DDs Bilateral lentiform nucleus  (1.5 T) (I) NA Right basal ganglia
CPEO ¼ chronic progressive external ophthalmoplegia; DDs ¼ deafness dystonia syndrome; dz ¼ disease; F ¼ female; FU ¼ follow-up; I ¼ intermediate echo
time; L ¼ long echo time; LS ¼ Leigh syndrome; M ¼ male; MELAS ¼ mitochondrial encephalopathy lactic acidosis and stroke-like episodes; MRI ¼ magnetic
resonance imaging; MRS ¼ magnetic resonance spectroscopy; NA ¼ not available; No. ¼ number; PS ¼ Pearson syndrome; Pt ¼ patient; S ¼ short echo time;
T ¼ tesla; T2WI ¼ T2-weighted images; * ¼ MRS shows lactate peak during deterioration of the disease course; “þ” ¼ positive finding; “” ¼ negative finding.
Fig. 2. Lactate peaks on brain magnetic resonance spectroscopy in Leigh
syndrome, Case 4. This 6-month-old male infant presents with sudden onset of
apnea and collapse, mimicking sudden infant death syndrome. Axial 3.0 T T2-
weighted imaging (TE/TR 80 ms/3000 ms) shows generalized cortical atrophy
and symmetric hyperintensity over the bilateral putamen. A volume of interest
is located at the left putamen. Magnetic resonance spectroscopy using short
echo time (35 milliseconds), intermediate echo time (144 milliseconds), and
long echo time (288 milliseconds) reveals a peak of lactate, a small inverted
doublet of lactate, and a peak of lactate at 1.33 ppm, respectively. Cho ¼
choline, Cr ¼ creatine, NAA ¼ N-acetylaspartate, Lip/aa ¼ lipids or branched
amino acids.
Table 2
Comparison of laboratory data, histochemical stain, EM examination of muscle spe
Pt No. Clinical
diagnosis
Lactate (mg/dL) OGLST R
Blood (3e12) CSF (10e25)
1 LS 11.6 NA þ 
2 LS 15.0 NA  
3 LS 23.0 NA þ 
4 LS 10.0 10.0 þ N
5 LS 8.0 13.0 þ 
6 LS 27.3 73.5 NA N
7 LS 12.0 NA þ N
8 MELAS 26.7 31.0 þ N
9 MELAS 13.0 NA NA N
10 MELAS 31.0 33.0 þ N
11 MELAS 14.0 NA þ N
12 CPEO 34.3 NA þ 
13 PS 41.3 NA þ 
14 DDs 12.5 NA þ 
Positive rate 10/14 (71.4%) 3/5 (60.0%) 11/12 (91.7%) 0
CPEO ¼ chronic progressive external ophthalmoplegia; CSF ¼ cerebrospinal fluid;
LS ¼ Leigh syndrome; MELAS ¼ mitochondrial encephalopathy lactic acid
mt ¼mitochondrial; NA ¼ not available; ND ¼ not detected; No. ¼ number; OGLS
RRF ¼ ragged-red fiber; “þ” ¼ positive finding; “” ¼ negative finding.
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ings, and mt gene analysis, are listed in Table 2. The corre-
lations of lactate levels of blood and CSF and lactate peaks on
MRS were inconsistent. Among 12 patients with lactate peaks
on MRS, eight (66.7%) had corresponding elevated levels of
blood lactate and four (33.3%) had normal levels of blood
lactate. Two patients without lactate peaks on MRS showed
elevated levels of blood lactate. Spinal tap was conducted on 5
patients with lactate peaks on MRS; two (40.0%) had normal
lactate levels of CSF and three (60.0%) had elevated lactate
levels.
Our observation showed the positive rates for diagnosing
syndromic MDs by using EM examination of muscle biopsy,
OGLST, lactate peak on MRS, and blood lactate level were
100%, 91.7%, 85.7%, and 71.4%, respectively.4. Discussion
The frequency of detectable elevation of lactate on MRS in
cases with syndromic MDs or definite MDs reported in the
literature ranges from 62.5% (5 of 8)12 to 81.3% (13 of 16).11
The detection of lactate peak on MRS is dependent on the
timing or severity of the disease, the location of the affected
tissues and the site of interrogation, lactate level of CSF, echo
times of MRS, or differences in types of MDs.12,16 In our case
series, the acquisition of lactate peaks on MRS was 85.7%. We
observed the detection rate of lactate peak was higher at acute
deterioration phase of the disease process than at stationary
phase of disease course. Our study revealed 66.7% and 60.0%
of patients with lactate peaks on MRS had elevated lactate
levels of blood and CSF, respectively. On the contrary, cases
with normal lactate levels in the blood and CSF still could
exhibit lactate peaks on MRS.cimens, mt gene analysis, and brain MRS in syndromic mitochondrial diseases





A þ ND þ
þ ND þ
A NA T8993G þ
A NA T10191C þ
A NA A3243G þ
A NA A3243G þ
A NA A3243G þ
A NA T3291C þ
þ 4.9 kbp deletion (nt 848213460) 
þ 6.0 kbp deletion (nt 7950-13993) þ
þ ND 
/7 (0%) 8/8 (100%) 10/14 (71.4%) 12/14 (85.7%)
DDs ¼ deafness dystonia syndrome; EM ¼ electron microscopic examination;
osis and stroke-like episodes; MRS ¼ magnetic resonance spectroscopy;
T¼ oral glucose lactate stimulation test; PS ¼ Pearson syndrome; Pt ¼ patient;
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in a normal brain MRI.17 The result of our study was consistent
with that finding, i.e. all 12 cases presented lactate peaks onMRS
accompanied with variable specific abnormal MRI features.
Spectra at 3.0 T have been demonstrated to improve
sensitivity compared with 1.5 T at short echo time, however,
spectra at long echo time exhibited similar signal-to-noise
ratio using both 1.5-T and 3.0-T magnets.18 Measurements of
lactate at intermediate echo time on 3.0-T MRS have been
reported to show reduced or absent signal intensity, a problem
not encountered at 1.5 T.19 In our study, we observed that
Cases 4, 7, 8, and 11 exhibited lactate peaks at short, inter-
mediate, and long echo times, respectively, on 3.0-T magnets.
However, Cases 5 and 9 showed lactate peaks at short and long
echo times, but none at intermediate echo time.
There is no single algorithm for diagnosing MDs. Several
diagnostic methods have been applied to help pediatricians
detect a mitochondriopathy earlier. In addition to clinically
specific phenotypes, our study showed positive rates of
abnormal mitochondrial configurations of muscle biopsy by
EM examination and OGLST for detecting syndromic MDs
were higher than that of MRS. However, MRS is a noninvasive
tool usable in children.
In conclusion, clinical diagnosis in children with mito-
chondriopathies is not easy because of variable clinical
symptoms.20 MRS examination is a noninvasive complemen-
tary tool for helping to corroborate the diagnosis of syndromic
MDs, especially in patients exhibiting signal changes on the
brain MRI and lactate peaks on MRS but a normal blood
lactate level. Furthermore, it helps determining whether
further invasive examinations and/or high-cost diagnostic tests
such as muscle biopsy and/or genetic analysis, are needed.
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